Cargando…

Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis

OBJECTIVE: Patients with anti‐melanoma‐differentiation‐associated 5 (anti‐MDA5)‐positive dermatomyositis (DM) share several striking similarities to patients with SARS‐CoV‐2. Our objective was to assess the prevalence of anti‐angiotensin converting enzyme‐2 (ACE2) immunoglobulin M (IgM) antibodies,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mecoli, Christopher A., Yoshida, Akira, Paik, Julie J., Lin, Cheng Ting, Danoff, Sonye, Hanaoka, Hironari, Rosen, Antony, Christopher‐Stine, Lisa, Kuwana, Masataka, Casciola‐Rosen, Livia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096520/
https://www.ncbi.nlm.nih.gov/pubmed/35229496
http://dx.doi.org/10.1002/acr2.11423
_version_ 1784705994024026112
author Mecoli, Christopher A.
Yoshida, Akira
Paik, Julie J.
Lin, Cheng Ting
Danoff, Sonye
Hanaoka, Hironari
Rosen, Antony
Christopher‐Stine, Lisa
Kuwana, Masataka
Casciola‐Rosen, Livia
author_facet Mecoli, Christopher A.
Yoshida, Akira
Paik, Julie J.
Lin, Cheng Ting
Danoff, Sonye
Hanaoka, Hironari
Rosen, Antony
Christopher‐Stine, Lisa
Kuwana, Masataka
Casciola‐Rosen, Livia
author_sort Mecoli, Christopher A.
collection PubMed
description OBJECTIVE: Patients with anti‐melanoma‐differentiation‐associated 5 (anti‐MDA5)‐positive dermatomyositis (DM) share several striking similarities to patients with SARS‐CoV‐2. Our objective was to assess the prevalence of anti‐angiotensin converting enzyme‐2 (ACE2) immunoglobulin M (IgM) antibodies, found in patients with severe SARS‐CoV‐2, in two independent anti‐MDA5‐positive DM cohorts. METHODS: Anti‐ACE2 IgM antibodies were assayed by enzyme‐linked immunosorbent assay (ELISA) in two anti‐MDA5‐positive DM cohorts: a predominantly outpatient North American cohort (n = 52) and a Japanese cohort enriched for new‐onset disease (n = 32). Additionally, 118 patients with SARS‐CoV‐2 with a spectrum of clinical severity were tested for anti‐MDA5 antibodies by ELISA. RESULTS: Five of fifty‐two (9.6%) North American patients and five of thirty‐two (15%) Japanese patients were positive for anti‐ACE2 IgM. In the North American cohort, all five patients with anti‐ACE2 IgM antibodies had proximal muscle weakness, had interstitial lung disease, were significantly more likely to receive pulse dose methylprednisolone (80% vs 30%, P = 0.043), and had worse forced vital capacity (median 59% predicted vs 78%, P = 0.056) compared with the anti‐ACE2‐IgM‐negative group. In the Japanese cohort, all five anti‐ACE2‐IgM‐positive patients also required pulse dose methylprednisolone, and three of five (60%) patients died. Japanese patients with anti‐ACE2 IgM had significantly worse oxygenation, as defined by a lower partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio (233 vs 390, P = 0.021), and a higher alveolar‐arterial oxygenation gradient (91 vs 23 mm Hg, P = 0.024) than the IgM‐negative group. CONCLUSION: We describe anti‐ACE2 IgM autoantibodies in two independent cohorts with anti‐MDA5‐positive DM. These autoantibodies may be biomarkers for severe disease and provide insight into disease pathogenesis.
format Online
Article
Text
id pubmed-9096520
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wiley Periodicals, Inc.
record_format MEDLINE/PubMed
spelling pubmed-90965202022-05-18 Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis Mecoli, Christopher A. Yoshida, Akira Paik, Julie J. Lin, Cheng Ting Danoff, Sonye Hanaoka, Hironari Rosen, Antony Christopher‐Stine, Lisa Kuwana, Masataka Casciola‐Rosen, Livia ACR Open Rheumatol Brief Report OBJECTIVE: Patients with anti‐melanoma‐differentiation‐associated 5 (anti‐MDA5)‐positive dermatomyositis (DM) share several striking similarities to patients with SARS‐CoV‐2. Our objective was to assess the prevalence of anti‐angiotensin converting enzyme‐2 (ACE2) immunoglobulin M (IgM) antibodies, found in patients with severe SARS‐CoV‐2, in two independent anti‐MDA5‐positive DM cohorts. METHODS: Anti‐ACE2 IgM antibodies were assayed by enzyme‐linked immunosorbent assay (ELISA) in two anti‐MDA5‐positive DM cohorts: a predominantly outpatient North American cohort (n = 52) and a Japanese cohort enriched for new‐onset disease (n = 32). Additionally, 118 patients with SARS‐CoV‐2 with a spectrum of clinical severity were tested for anti‐MDA5 antibodies by ELISA. RESULTS: Five of fifty‐two (9.6%) North American patients and five of thirty‐two (15%) Japanese patients were positive for anti‐ACE2 IgM. In the North American cohort, all five patients with anti‐ACE2 IgM antibodies had proximal muscle weakness, had interstitial lung disease, were significantly more likely to receive pulse dose methylprednisolone (80% vs 30%, P = 0.043), and had worse forced vital capacity (median 59% predicted vs 78%, P = 0.056) compared with the anti‐ACE2‐IgM‐negative group. In the Japanese cohort, all five anti‐ACE2‐IgM‐positive patients also required pulse dose methylprednisolone, and three of five (60%) patients died. Japanese patients with anti‐ACE2 IgM had significantly worse oxygenation, as defined by a lower partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio (233 vs 390, P = 0.021), and a higher alveolar‐arterial oxygenation gradient (91 vs 23 mm Hg, P = 0.024) than the IgM‐negative group. CONCLUSION: We describe anti‐ACE2 IgM autoantibodies in two independent cohorts with anti‐MDA5‐positive DM. These autoantibodies may be biomarkers for severe disease and provide insight into disease pathogenesis. Wiley Periodicals, Inc. 2022-03-01 /pmc/articles/PMC9096520/ /pubmed/35229496 http://dx.doi.org/10.1002/acr2.11423 Text en © 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Mecoli, Christopher A.
Yoshida, Akira
Paik, Julie J.
Lin, Cheng Ting
Danoff, Sonye
Hanaoka, Hironari
Rosen, Antony
Christopher‐Stine, Lisa
Kuwana, Masataka
Casciola‐Rosen, Livia
Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis
title Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis
title_full Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis
title_fullStr Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis
title_full_unstemmed Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis
title_short Presence and Implications of Anti‐Angiotensin Converting Enzyme‐2 Immunoglobulin M Antibodies in Anti‐Melanoma‐Differentiation‐Associated 5 Dermatomyositis
title_sort presence and implications of anti‐angiotensin converting enzyme‐2 immunoglobulin m antibodies in anti‐melanoma‐differentiation‐associated 5 dermatomyositis
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096520/
https://www.ncbi.nlm.nih.gov/pubmed/35229496
http://dx.doi.org/10.1002/acr2.11423
work_keys_str_mv AT mecolichristophera presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis
AT yoshidaakira presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis
AT paikjuliej presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis
AT linchengting presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis
AT danoffsonye presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis
AT hanaokahironari presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis
AT rosenantony presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis
AT christopherstinelisa presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis
AT kuwanamasataka presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis
AT casciolarosenlivia presenceandimplicationsofantiangiotensinconvertingenzyme2immunoglobulinmantibodiesinantimelanomadifferentiationassociated5dermatomyositis